RxDoctor Payments Data

Carly Sayers, NP

Nurse Practitioner · Athens, GANPI 1336556653

Payments from drug & device makers

$8,361in general payments, 2019–2025

Across 506 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$753
  • Takeda Pharmaceuticals U.S.A., Inc.$482
  • Ardelyx, Inc.$413
  • Sanofi$326
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$8,17798%
  • Education$1842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,361 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$78,208
Medicare patients
462
Services billed
888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab38$345,555
XifaxanRifaximin101$311,975
CreonLipase/Protease/Amylase26$114,568
IbsrelaTenapanor Hcl26$103,372
LinzessLinaclotide90$97,210
MotegrityPrucalopride Succinate38$47,095
Mesalamine43$38,090
VoqueznaVonoprazan Fumarate28$32,116
Dexlansoprazole DrDexlansoprazole95$31,139
TrulancePlecanatide24$29,871
ErythromycinErythromycin Base47$26,275
Colestipol Hcl163$12,273
Budesonide ErBudesonide11$10,884
Budesonide DrBudesonide15$10,837
Lubiprostone79$10,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,930$341,846125 claims
AbbVieCreon, Linzess$2,565$211,779116 claims
Ardelyx, Inc.Ibsrela$413$103,37226 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$482$47,09538 claims
Phathom Pharmaceuticals, Inc.Voquezna$157$32,11628 claims
PfizerEliquis$261$3,18511 claims
SandozLansoprazole$66$84228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →